Evidence map›Paper›PMID 41777111›Full record

ArticleBioconjugate chemistry2026

NanoBRET Tracer Development for Class I Bromodomain Target Engagement in Live Cells.

Molly S Sneddon, Chun-Ju Tsou, Xiang Fu, Anang A Shelat, William C K Pomerantz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Molly S SneddonDepartment of Chemistry, University of Minnesota, 207 Pleasant St. SE, Minneapolis, Minnesota 55455, United States.
Chun-Ju TsouDepartment of Chemistry, University of Minnesota, 207 Pleasant St. SE, Minneapolis, Minnesota 55455, United States.
Xiang FuDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Anang A ShelatDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.ORCID 0000-0002-6266-2910
William C K PomerantzDepartment of Chemistry, University of Minnesota, 207 Pleasant St. SE, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-0163-4078

Funding

Training the Next Generation of Chemical BiologistsT32GM132029 · NIGMS · UNIVERSITY OF MINNESOTA · PI Erin Elizabeth Carlson, William Charles Krause Pomerantz · 2019 to 2026
$2.7M
Targeting the chromatin binding domains of BPTF for neuroblastoma epigenetic therapyR01CA290805 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Marcus Fischer, William Charles Krause Pomerantz · 2025 to 2026
$1.5M
NCI NIH HHS R01 CA290805NIGMS NIH HHS T32 GM132029
6 · The paper itself

Abstract

Epigenetic reader proteins, such as bromodomains, are often associated with diseases such as cancer and inflammation. Bromodomain and extra-terminal (BET) bromodomain inhibitors have been studied extensively; however, non-BET bromodomains are understudied. Moreover, available high-throughput biological assays to assess inhibitors are limited. One non-BET bromodomain-containing protein, BPTF, has a recently reported inhibitor, BZ1, with an in vitro affinity of 6.3 nM. Additionally, BZ1 is known to be nonselective toward other class I bromodomains PCAF, GCN5, and CECR2. Here, we use a BZ1 analog, BZ1-THQ, to design a small-molecule NanoBRET tracer,

Indexed as

Transcription FactorsBromodomain Containing ProteinsHEK293 CellsHumansp300-CBP-Associated FactorProtein DomainsBromodomain Containing Proteinsp300-CBP-Associated FactorTranscription Factors

Identifiers

PMID41777111
PMCPMC13006835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.